Epigenomics AG (EPGNF)
Epigenomics AG operates in the Medical - Specialties industry of the Healthcare sector, headquartered in Heidelberg, BE, DE. The stock last traded at $1.12, up 0.00% on the session, giving a market capitalisation of $1.0M. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of -2479.2%. Its beta of 0.87 implies it has historically moved less than the broad market.
Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA and, HCCBloodTest, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma. The company was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo G. Gut in 1998 and is headquartered in Berlin, Germany.
Epigenomics AG is most often compared with the following Healthcare names: